Advertisement
New Zealand markets open in 2 hours 25 minutes
  • NZX 50

    11,872.64
    +130.76 (+1.11%)
     
  • NZD/USD

    0.6172
    -0.0016 (-0.25%)
     
  • ALL ORDS

    8,002.50
    +39.40 (+0.49%)
     
  • OIL

    78.38
    -0.12 (-0.15%)
     
  • GOLD

    2,319.50
    -35.30 (-1.50%)
     

Why AbbVie (ABBV) is a Top Value Stock for the Long-Term

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors.

Achieving those goals is made easier with the Zacks Style Scores, a unique set of guidelines that rates stocks based on popular investing methodologies, namely value, growth, and momentum. The Style Scores can help you narrow down which stocks are better for your portfolio and which ones can beat the market over the long-term.

Why Investors Should Pay Attention to This Value Stock

Different than growth or momentum investors, value-focused investors are all about finding good stocks at good prices, and discovering which companies are trading under what their true value is before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, and Price/Cash Flow to help pick out the most attractive and discounted stocks.

ADVERTISEMENT

AbbVie (ABBV)

North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal has transformed AbbVie’s portfolio by lowering its dependence on Humira, its flagship product, which has lost patent protection in Europe as well as the United States. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica. Its newest immunology drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.

ABBV boasts a Value Style Score of B and VGM Score of B, and holds a Zacks Rank #3 (Hold) rating. Shares of AbbVie are trading at a forward earnings multiple of 14.2X, as well as a PEG Ratio of 2, a Price/Cash Flow ratio of 10.1X, and a Price/Sales ratio of 5.2X.

A company's earnings performance is important for value investors as well. For fiscal 2024, nine analysts revised their earnings estimate higher in the last 60 days for ABBV, while the Zacks Consensus Estimate has increased $0.09 to $11.26 per share. ABBV also holds an average earnings surprise of 2.7%.

With strong valuation and earnings metrics, a good Zacks Rank, and top-tier Value and VGM Style Scores, investors should strongly think about adding ABBV to their portfolios.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

AbbVie Inc. (ABBV) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research